ARTICLE | Clinical News
Necuparanib: Phase I/II data
October 20, 2014 7:00 AM UTC
Top-line data from 12 evaluable patients with advanced metastatic pancreatic cancer in the open-label, dose-escalation, U.S. Part A of a Phase I/II trial showed that once-daily oral necuparanib plus ...